MODRASTANE
LOE Approachingtrilostane
NDAORALCAPSULE
Approved
Dec 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MODRASTANE (trilostane) is an oral small-molecule steroid synthesis inhibitor approved in 1984 for treating adrenocortical disorders. It reduces cortisol production by inhibiting 3β-hydroxysteroid dehydrogenase in the adrenal cortex. The drug is used primarily in veterinary medicine for canine hyperadrenocorticism, though human indications may include severe hypertension or Cushing's syndrome.
LOE Approaching
With LOE approaching and minimal current commercial activity, team size is likely small and focused on transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Trilostane for Androgen-Independent Prostate Cancer
Started Mar 2004
24 enrolled
Prostate CancerProstate Adenocarcinoma
Career Relevance
No current job postings are linked to MODRASTANE, indicating minimal active hiring around this product. Working on this asset offers limited growth opportunity but potential value in legacy product management, regulatory affairs, or transition planning expertise.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.